Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below. Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.
Sudarshan Rajagopal, MD, PhD
I take care of patients with pulmonary hypertension (PH). I also research signaling pathways that are altered in the development of PH in rodent models of the disease. PH covers a wide spectrum of diseases, from the rare pulmonary arterial hypertension (prevalence of 15 in one million) to complications of more common heart and lung disease. PH typically leads to complications through its effects on the heart, leading to heart failure. At the Duke Center for Pulmonary Vascular Disease we see a number of patients with PH and offer all available therapies, including continuous intravenous infusion, inhaled therapies, and surgical options.
Clinical Focus and Research
My research is on receptor signaling in pulmonary hypertension (PH). There are a number of receptor abnormalities in PH, and I am interested in how these receptors signal to their downstream targets. This understanding could lead to the development of new drugs for treating PH.
View Sudarshan Rajagopal's publications on PubMed
- First Health
- Gateway Health Alliance
- Halifax Physician-Hospital Organization
- MultiPlan / Private Healthcare Systems
- OneNet PPO
Industry Relationships and Collaborations
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Gilead Sciences, Inc.
- United Therapeutics Corp.